Biomarkers and cardiovascular events in community-acquired pneumonia

Introduction: Community-acquired pneumonia (CAP) increases the risk of cardiovascular (CV) events. Aim: To study the occurrence of CV events in patients with CAP and their link with biomarkers. Method: Prospective study in a Spanish hospital in 572 patients with CAP followed for 1 year. We collected comorbidities, CV events (from admission to 1 year) and biomarkers: proBNP, troponins (TnT), endothelin, proadrenomedullin (proADM), procalcitonin (PCT). We performed ROC curve of biomarkers for CV events. Results: We studied 322 patients with biomarkers; 65 (20.2%) had CV events (39 after discharge). Biomarkers are shown in table1. The areas under the ROC curve (AUC) of biomarkers day 1 for CV events: TnT 0.77(95%CI 0.71-0.84), proBNP 0.77(0.70-0.84), endothelin 0.70(0.61-0.80), proADM 0.70(0.60-0.79), PCT 0.56(0.46-0.66). The AUC of day 4: proADM 0.77(0.70-0.85), endothelin 0.75(0.67-0.83), proBNP 0.75(0.67-0.82), TnT 0.75(0.68-0.82), PCT 0.56(0.47-0.66). Conclusions: Biomarkers may predict early and long-term CV events in CAP. TnT and proBNP during the 1st day and proADM the 4th day are the best biomarkers predicting CV events.